Purpose Of Review: Trichomonas vaginalis is the most prevalent sexually transmitted parasite in the USA; resistant infection is emerging. New drug therapies and dosing regimens of standard therapies are being studied to treat resistant infection.
Recent Findings: Diagnosis of trichomoniasis has become more sensitive, specific, and widely available with the advent of nucleic acid amplification tests (NAATs). Women with resistant trichomoniasis should be treated with high-dose regimens of metronidazole or tinidazole. Alternative treatment options have been described, and there has been some success particularly with high-dose tinidazole/intravaginal paromomycin cream combination, intravaginal boric acid, and intravaginal metronidazole/miconazole. Resistant trichomoniasis is a growing public health concern with implications for long-term health consequences. More data are needed to further evaluate mechanisms by which resistance occurs as well as promising therapies for those affected.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11908-019-0687-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Trichomoniasis, caused by the parasite , is the most common non-viral sexually transmitted infection. Current treatment relies exclusively on 5-nitroimidazole drugs, with metronidazole (MTZ) as the primary option. However, the increasing prevalence of MTZ-resistant strains poses a significant challenge, particularly in the current absence of alternative therapies.
View Article and Find Full Text PDFDevelopment of a New Rapid Simultaneous Molecular Assay for the Detection of STI Pathogens and Drug Resistance-Associated Mutations.
Mol Diagn Ther
January 2025
Department of Infectious Diseases, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan.
Background: In the diagnosis of sexually transmitted infections, there has been a demand for multiple molecular assays to rapidly and simultaneously detect not only pathogens but also drug resistance-associated mutations.
Methods: In this study, we developed a new rapid simultaneous molecular assay for the detection of Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Mycoplasma genitalium, and M. genitalium macrolide (23S rRNA gene, A2058/A2059) and fluoroquinolone (ParC gene, S83I) drug resistance-associated mutations in approximately 35 minutes.
Chromatin accessibility and gene expression in the parasite Trichomonas vaginalis.
Res Sq
December 2024
Instituto Tecnológico Chascomús (INTECH), CONICET-UNSAM.
, the most common non-viral sexually transmitted parasite, causes more than 270 million infections annually. The infection's outcome varies greatly depending on different factors that include variation in human immune responses, the vaginal microbiome, and the inherent virulence of the strain. Although the pathogenicity of the different strains depends, at least partially, on differential gene expression of virulence genes; the regulatory mechanisms governing this transcriptional control remain incompletely understood.
View Article and Find Full Text PDFLong-term management of refractory vaginal trichomoniasis following initial metronidazole treatment failure: A case series.
Jpn J Infect Dis
December 2024
Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan.
Guidelines for sexually transmitted infections recommend oral metronidazole (MNZ) as the first-line treatment option for vaginal trichomoniasis; however, there have been cases of prolonged symptoms or recurrence after treatment. To consider appropriate treatment strategies for refractory vaginal trichomoniasis, we conducted a retrospective cohort study. We reviewed the medical records of patients who tested positive for Trichomonas vaginalis (T.
View Article and Find Full Text PDF[Determination of Gene Mutations Associated with Macrolide and Fluoroquinolone Resistance in Patients Infected with Mycoplasma genitalium].
Mikrobiyol Bul
October 2024
Hacettepe University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Türkiye.
A sexually transmitted bacterium, Mycoplasma genitalium has varying rates of reported resistance to macrolide and some fluoroquinolone group antimicrobials recommended for the treatment of its infections. It is currently recommended that the treatment of these must be planned according to macrolide resistance status. The aim of this study was to determine the presence of macrolide resistance associated mutations (MRM) and fluoroquinolone resistance associated mutations (QRM) in patients infected with M.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!